ROSWELL, Ga. (PRWEB)
May 08, 2023

Aquitas Solutions, a leading provider of Enterprise Asset Management (EAM) and IoT solutions that optimize asset-intensive industries, recently announced the completion of their EAM consolidation project with a globally-recognized healthcare provider.

Through the combined effort of leaders involved in this EAM implementation, healthcare leadership will gain greater visibility into trends and risks, improve reporting around assets and operations, and the capability to quickly reallocate labor. This enhanced information available in a single EAM solution with a disconnected mobile solution can help promote long-term cost savings and a more efficient workforce.

“Our team appreciates the opportunity to support an organization that helps so many in their time of need,” said Jeff Brown, CEO of Aquitas Solutions. “The new asset management solution will simplify managing facility infrastructure and maintenance activities for the organization’s hospitals and research facilities. Renowned healthcare facilities require operational excellence, and the solution that’s now in place will support staff in efforts to maintain an elevated standard of care in compliance with all regulatory agency requirements.”

About Aquitas Solutions

Aquitas brings 20+ years of EAM experience and a proven record of success across many industries. As an expert in implementing and supporting Maximo, Aquitas is uniquely positioned as a strong resource for clients ready to rethink their operations and facility maintenance strategy. The company’s Connected Maintenance portfolio is comprised of Maximo, IoT and Augmented Reality technologies that advance current maintenance practices while leveraging existing systems.

Based in Atlanta, GA, Aquitas’ leadership team and management consultants have industry leading enterprise asset management experience helping clients leverage their EAM system to optimize performance and improve productivity and service levels across the entire spectrum of their organization.

Share article on social media or email:

Dr Garbelli feels that by fostering a successful collaboration between empowered physicians and healthcare stakeholders, high quality and sustainable healthcare can be achieved.

LONDON (PRWEB)
May 08, 2023

According to the American Medical Association, physician burnout is an epidemic in the U.S. health care system, with nearly 63% of physicians reporting signs of burnout, such as emotional exhaustion and depersonalization, at least once per week.

In “The Doctor’s Voice,” author Dr. Pietro Emanuele Garbelli hopes to provide guidance and assistance to unveil and assist physicians struggling with burnout and overwhelmed by their workloads. It offers solutions to help them stay happy and healthy, while still practicing medicine at its most rewarding level.

Dr Garbelli feels that by fostering a successful collaboration between empowered physicians and healthcare stakeholders, high quality and sustainable healthcare can be achieved.

“Having personally experienced and observed amongst colleagues how daily frustrations lead to burnout and a desire to escape the medical profession,” said Dr. Garbelli, “I know how damaging and incapacitating this experience is for physicians.”

Dr. Garbelli is a specialist in Acute Internal Medicine, a clinical director, and a healthcare consultant. Having witnessed and experienced inefficiencies, frustrations, and struggles as a patient, a relative, and a provider, he uses the lessons learned as a powerful catalyst to provide medical thought leadership. Through years of professional coaching and personal development, Dr. Garbelli learned how problems that physicians encounter could be turned into opportunities for solutions that shape the future of healthcare.

“Retaining an invaluable medical workforce is just one of the benefits of tackling doctors’ frustrations,” said Dr. Garbelli. “Unleashing the potential of doctors’ skills and contributions beyond mere clinical duties can empower healthcare organizations, stakeholders and decision-makers with the data required to achieve their targets.”

“The Doctor’s Voice: Empowering Solutions to Physicians’ Frustrations, Burnout and Healthcare Inefficiencies”

By Dr. Pietro Emanuele Garbelli

ISBN: 9781665730075 (softcover); 9781665730068 (hardcover); 9781665730082 (electronic)

Available at Archway Publishing, Amazon and Barnes & Noble

About the author

Dr. Pietro Emanuele Garbelli received his medical degree from the University of Milan and his Masters in Acute Internal Medicine from the University of Florence. He currently resides in London, where he also practices at North Middlesex University Hospital.

To learn more, please visit http://www.DrGarbelli.com

Share article on social media or email:

“With my new informative website, I am excited to help even more Miami Beach, FL, area clients schedule services and attain the best versions of themselves with minimally or non-surgical cosmetic enhancements and aesthetic procedures that offer amazing outcomes,” says founder Lisa Lifshitz.

MIAMI BEACH, Fla. (PRWEB)
May 08, 2023

The elite cosmetic studio, located at 820 W 41st St, Suite 210, in Miami Beach, FL, is a cutting-edge facility, providing incredible outcomes using the latest options in aesthetic procedures, ranging from Botox® and fillers to skin rejuvenation with lasers, peels and lip injections. Top skincare expert, Lisa Lifshitz, PA-C, and the team at LL Aesthetics are dedicated to providing exceptional cosmetic transformations for clients to help them look their best at any age, delivering a thorough consultation to find the best options to meet individual cosmetic goals. The new state-of-the-art website, http://www.llaestheticsmiami.com, allows clients to schedule appointments directly on the site and read patient testimonials. It also highlights several cosmetic options that clients can benefit from to restore youthful skin, including treatments that can increase collagen or erase signs of aging, such as, Morpheus8 skin tightening, IPL photofacial, VI facial peels, Botox® and other neuromodulator injections, dermal filler injections, PRP and microneedling. LL Aesthetics has invested in advanced aesthetic technology, ranging from the latest injectables to laser and RF treatments that can safely enhance the skin’s appearance.

“With my new informative website, I am excited to help even more Miami Beach, FL, area clients schedule services and attain the best versions of themselves with minimally or non-surgical cosmetic enhancements and aesthetic procedures that offer amazing outcomes,” says founder Lisa Lifshitz.

More about Lisa Lifshitz:

Lisa Lifshitz, PA-C is the founder of LL Aesthetics and has dedicated her career to providing exceptional care for patients. Ms. Lifshitz has an impressive background and experience that have earned her an excellent reputation for her work throughout the greater Miami Beach, FL, area. She obtained her BA in psychology and biology with honors, Magna Cum Laude, from Touro College in 2011. To continue her education, she entered Barry University-Masters of Clinical Medical Science program and graduated at the top of her class. After completing her education, Lisa became a licensed physician assistant. She is licensed by the Florida Department of Health and certified by the National Commission on Certification of Physician Assistants. She has worked with some of the top dermatologists in the area and has extensive experience in aesthetic medical and skincare treatments. To schedule an appointment or consultation, please visit http://www.llaestheticsmiami.com or call 786-785-6005.

Share article on social media or email:

“It is always such an honor to be recognized by my peers for this award, and I consider it a significant professional accomplishment,” says Dr. Gregory Levitin.

NEW YORK (PRWEB)
May 08, 2023

Dr. Gregory Levitin has been selected as a 2023 Top Doctor® by Castle Connolly. First selected in 2018, he has continued to earn this impressive award for his expertise in Otolaryngology. For patients seeking the best care, Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com, as well as in a wide variety of partner publications, magazines and affiliate websites. After a thorough and rigorous vetting process, around 5% of the nation’s licensed physicians are selected as Castle Connolly Top Doctor for their specialty.

As a leading expert in delivering treatment for chronic sinusitis, Dr. Gregory Levitin understands the importance of ear, nose and throat health, and how problems and concerns can affect overall well-being. His personalized, comprehensive approach to care provides patients with the most effective options available, whether the treatment plan is with medication, minimally invasive surgery or a non-invasive in-office procedure. He primarily offers minimally invasive procedures at his clinic, City Sinus Care, to open up sinus cavities, reduce snoring, and improve breathing overall.

Dr. Levitin is most widely-known for his expertise and experience in in-office balloon sinuplasty procedures, which avoids the risks of general anesthesia or more invasive surgery. In addition, Dr. Levitin is also a highly sought-after specialist when it comes to treating vascular birthmarks in children and adults. He offers medical, laser, and surgical treatment for hemangiomas, venous malformations, lymphatic malformations, port-wine stains and other vascular tumors; and is one of just a handful of specialists across the entire country that is trained to treat vascular birthmarks.

“It is always such an honor to be recognized by my peers for this award, and I consider it a significant professional accomplishment,” says Dr. Gregory Levitin.

More about Dr. Gregory Levitin:

Dr. Gregory Levitin, MD, FACS is a board-certified otolaryngologist-head and neck surgeon and fellow of the American Academy of Otolaryngology (AAO-HNS). He is also an assistant clinical professor in the Department of Otolaryngology at The New York Eye and Ear Infirmary and runs the Vascular Birthmark Center of New York. Dr. Levitin’s areas of expertise include balloon sinuplasty, endoscopic sinus surgery, allergic and chronic sinus disease, snoring and obstructive sleep disorders, tonsil and adenoid disease, vascular birthmarks and tongue/lip ties.

For more information about City Sinus Care located at Columbus Circle, 200 W. 57th Street, Suite 1410, please call 212-784-6643 or visit http://www.citysinuscare.com.

To reach the Vascular Birthmark Center of New York, also located at 200 W. 57th St., Suite 1410, visit http://www.birthmarkcare.com or call (212) 316-0616.

Share article on social media or email:

“We received FDA feedback that has been incorporated into our development program. We expect to initiate our clinical trial in 2024 and receive results in 12 months, to be followed by a Phase IIA trial in ALL patient subsets including those with T-ALL and Ph-like ALL.” Dr. Philip Breitfeld, CMO

HOUSTON (PRWEB)
May 08, 2023

Fannin Partners, LLC has received a $2 million Small Business Innovation Research (SBIR) Phase II grant from the National Cancer Institute (NCI) to advance spin-out Allterum Therapeutics’ 4A10 monoclonal antibody for the treatment of acute lymphoblastic leukemia (ALL), the most frequently diagnosed cancer in children. The SBIR grant will help support a Phase I clinical trial to assess the safety and activity of 4A10 as monotherapy and will determine pharmacokinetics, pharmacodynamics, and tumor biomarkers associated with the therapy.

Allterum’s 4A10 antibody, which was invented at NCI by senior investigator Dr. Scott Durum and his collaborators, targets CD127 (the interleukin-7 receptor subunit alpha; IL-7R). The antibody will initially be focused on patients with relapsed/refractory ALL with the expectation of expansion into the first-line setting. 4A10 is also being evaluated for the treatment of patients with other CD127-expressing malignancies.

Allterum plans to conduct its ALL Phase I trial in partnership with the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, which includes 31 leading pediatric cancer centers, along with key adult leukemia centers such as The University of Texas MD Anderson Cancer Center. “We have completed our Pre-IND meeting and received FDA feedback that has been incorporated into our development program,” commented Dr. Philip Breitfeld, Chief Medical Officer of Allterum. “We expect to initiate our clinical trial in 2024 and receive results in 12 months, to be followed by a Phase IIA trial in ALL patient subsets including those with T-ALL and Ph-like ALL.”

“Allterum’s monoclonal antibody is a much-needed therapeutic for patients with ALL who have exhausted known effective treatment options,” said Dr. Eric Schafer, Associate Professor in the Department of Pediatrics, Section of Hematology/Oncology at Baylor College of Medicine and Texas Children’s Hospital who will serve as the Chair of the TACL study. “Current chemotherapies come with significant toxicity, which limits their effective use. Allterum’s targeted therapy is designed to be effective in these patient populations, with greatly reduced side effects.”

Since ALL is an ultra-orphan indication with an unmet medical need, Allterum has qualified for programs to facilitate and expedite development of new drugs for rare diseases. The 4A10 antibody has received Orphan Drug Designation and Rare Pediatric Disease Designation from FDA, providing an accelerated path to approval, and potentially qualifying for a Pediatric Priority Review Voucher. In addition, Allterum’s 4A10 antibody has the potential for label extension to include the front-line treatment of patients with T-cell ALL and high-risk B-cell ALL, other T-cell malignancies, and CD127-expressing subsets of other hematologic cancers.

Allterum has been spun out of Fannin, and early work was funded by a $2.9M grant from the Cancer Prevention and Research Institute of Texas (CPRIT) matched by a $1.8M Series Seed financing that was led by Fannin. This work included manufacturing scale-up and preclinical toxicology activities. The SBIR Phase II grant from NCI, together with additional fundraising, will advance the 4A10 antibody to an Investigational New Drug (IND) filing and the first-in-human clinical trial.

“We appreciate the additional validation by the NCI provided by the SBIR award and the funding that will support the further development of 4A10,” said Dr. Atul Varadhachary, Managing Partner of Fannin and President and CEO of Allterum. “We are excited about the potential for this targeted treatment modality to address the needs of patients with ALL and possibly other CD127-expressing cancers.”

Share article on social media or email:

So how can one incorporate different types of data from patients into clinical trials?

TORONTO, Ontario (PRWEB)
May 08, 2023

Series Description

The value of real-world data is clear. The acceptance of real-world evidence (RWE) is growing. But is this enough to propel RWE from being a nice-to-have to a must-have? PicnicHealth is hosting a four-part webinar series to reframe the “ROI” for RWE generation and tackle the question: beyond the return on investment for RWE, what is the risk of inaction?

Webinar Description

With increasing applications of real-world data (RWD) upstream in the drug development lifecycle, it’s critical to recognize that there is no one-size-fits-all approach. So how can one incorporate different types of data from patients into clinical trials? Through conversation with a panel of experts from the biopharma industry and health technology companies, the featured speakers will discuss scenarios when patient-mediated, tokenized and/or site-based approaches are warranted. Speakers will share their unique perspectives on the importance of a tailored yet flexible strategy and the potential value this can unlock for researchers and patients alike.

Join today to explore design considerations for incorporating different types of real-world data into clinical trials.

Join Gaelan Ritter, Head of Analytics Innovation and Digital Health, Bristol-Myers Squibb; Andrew Larsen, VP of Partnerships, PicnicHealth; Jim Coutcher, Senior Director, Global Head of Emerging Methods and Solutions, Real World Solutions, IQVIA; and Evelyn Pyper (Moderator), Evidence Strategist, PicnicHealth, for the live webinar on Wednesday, May 24, 2023, at 12pm EDT (5pm BST/UK).

For more information, or to register for this event, visit Real-World Data By Design — Incorporating Different Data Types into Clinical Trials.

ABOUT PICNICHEALTH

PicnicHealth is a healthcare technology company that partners directly with patients to build deep real-world datasets. The company leverages state-of-the-art machine learning, combined with human curation, to port complete medical records into an easy-to-use online application. The platform gives patients unprecedented access to and control over their medical records and, with their consent, the opportunity to contribute this valuable data to further scientific research. Learn more at PicnicHealth.com.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Embark Behavioral Health Logo

“Our team is dedicated to providing compassionate and evidence-based care to support the well-being of young people and their families in our community,” said the location’s executive director, Dr. Myra Irani, who has a doctorate in clinical psychology.

DENVER (PRWEB)
May 08, 2023

To best help preteens, teens, young adults, and their families heal, Embark Behavioral Health, a leading network of mental health treatment programs for young people, is now enrolling clients at a new outpatient therapy clinic in Greenwood Village, Colo.

Conveniently located near Denver, Aurora, and Lakewood, the clinic offers a comprehensive range of services as part of the company’s robust continuum of care. Those services include a therapeutic day treatment program, also known as a partial hospitalization program (PHP), and an intensive outpatient program (IOP).

“Our team is dedicated to providing compassionate and evidence-based care to support the well-being of young people and their families in our community,” said the location’s executive director, Dr. Myra Irani, who has a doctorate in clinical psychology. “With this new facility, we hope to reach even more children and families in need and empower them on their journey toward healing and resilience.”

The Greenwood Village clinic is Embark’s first location in Colorado, located at 5340 S. Quebec St., Suite 205 N, adjacent to Highway 88 and Interstate 25.

Embark’s entry into the Denver market will support the Colorado community as the youth mental health crisis reaches alarming levels. In May 2021, Children’s Hospital Colorado announced its first-ever state of emergency for youth mental health. As a result of the alarming levels, hospitals, therapy centers, behavioral health hospitals, and local schools are overwhelmed with children and their families who are dealing with the repercussions of this escalating mental health crisis. With its new clinic, Embark can provide mental health services to those families who are actively struggling in the Denver area.

The Embark Difference

Offering programs accredited by The Joint Commission, Embark prioritizes delivering optimal care and adheres to superior safety standards. The company takes a personal approach to family therapy by treating families as a whole, emphasizing evidence-based and relationship-centered techniques. In fact, the research team collects thousands of data points and shares feedback with families so therapists can adjust treatment accordingly, ensuring families receive the best care.

Embark’s diverse programs encompass individual, group, and family therapy, therapeutic/peer mentoring, home health care services, addiction treatment, and parent coaching. These programs address a wide range of issues, such as:

• Attention-deficit/hyperactivity disorder (ADHD)
• Anger/mood Regulation  
• Anxiety  
• Bipolar disorder  
• Borderline personality disorder  
• Bullying  
• Depression  
• Family conflict  
• Self-harm/cutting  
• Social isolation  
• Substance use  
• Technology addiction  

The Greenwood Village Clinic: A Closer Look

“For adolescents, teens, and young adults living in the Denver area, our outpatient services provide an excellent option for accessing therapy conveniently and locally,” said the location’s clinical director, Emmett Wells, a licensed clinical social worker.

To celebrate the clinic’s opening, Embark is hosting a ribbon cutting and Mental Health Awareness Month kickoff on Monday, May 8, from 5-7 p.m. The event will include the contemporary story of the living Native American art form known as powwow, performed by The LaPointe-Roy family. To RSVP for the event, visit the Eventbrite page.

In addition to launching Embark’s first Colorado outpatient clinic, recent Embark milestones include:

• Embark Outpatient Clinic in Berwyn, PA earned Main Line Parent’s “Best Mental Health Services Provider for Teens” in their area for the second consecutive year.
• Adding a Scottsdale outpatient therapy clinic featuring an IOP and a therapeutic day treatment program.
• Expanding online services with Embark Virtual IOP. Virtual IOP is an insurance-reimbursable program available to residents in various states across the country. It’s ideal for preteens, teens, and young adults as part of an after- and continuing-care plan ─ for example, when they’re stepping down from a higher level of care, such as residential treatment or wilderness therapy, or up from a lower level of care, such as weekly individual therapy.

For more information about Embark Behavioral Health, visit the website.

ABOUT EMBARK BEHAVIORAL HEALTH

Embark Behavioral Health is a leading network of outpatient centers and residential programs offering premier mental health treatment for preteens, teens, and young adults. Dedicated to its big mission of reversing the trends of teen and young adult anxiety, depression, and suicide by 2028, Embark offers a robust continuum of care with different levels of service and programming; has a deep legacy of over 25 years serving youths; works with families to adjust treatment in real time to improve results; treats the entire family using an evidence-based approach; and offers the highest levels of quality care and safety standards. For more information about Embark or its treatment programs, including virtual services, intensive outpatient programs (IOPs), therapeutic day treatment programs, also known as partial hospitalization programs (PHPs), short-term residential treatment, wilderness therapy, and long-term residential treatment, visit http://www.embarkbh.com.

Share article on social media or email: